Close Menu

Natera

Verinata Health said last week that it is seeking a declaratory judgment from a federal court that its sequencing-based methods for prenatal diagnostics do not infringe on a patent held by Sequenom.

Verinata Health presented results from its fetal aneuploidy study this week at the Annual Society for Maternal-Fetal Medicine meeting and has set a March 1 launch date for its noninvasive sequencing-based test, which it will market for the detection of trisomy 21, 18, and 13.

This article was originally published Feb. 3.
Sequenom has published the results of a study demonstrating that its noninvasive MaterniT21 test, which detects Down syndrome in a fetus by sequencing maternal plasma, can also detect trisomy 18 and trisomy 13.

This story was originally published Jan. 27.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Sequenom has sued both Aria Diagnostics and Natera, accusing the companies of infringing a Sequenom patent with their respective noninvasive trisomy 21 and paternity tests.

By Monica Heger

Sequenom has sued both Aria Diagnostics and Natera, accusing the companies of infringing a Sequenom patent with their respective noninvasive trisomy 21 and paternity tests.

By Monica Heger
This story was originally published Jan. 17.
Aria Diagnostics is planning to launch a clinical trial of its noninvasive sequencing-based trisomy 21 test in 25,000 women.

Pages

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.

Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.

In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.